Related Experiment Video
Updated: Jan 15, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Treatment of systemic vasculitis
1Clinical Associate Professor of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
New treatments show promise for systemic vasculitis, including ANCA-associated vasculitis (AAV). However, issues with new classification criteria need addressing for widespread adoption in clinical trials.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Systemic vasculitis encompasses several rare autoimmune diseases.
- Effective management of vasculitis requires up-to-date treatment strategies.
Purpose of the Study:
- To review recent impactful data on treating systemic vasculitic conditions.
- Focus on ANCA-associated vasculitis (AAV), giant cell arteritis, polymyalgia rheumatica, and Takayasu arteritis.
Main Methods:
- Review of recent clinical trials and real-world registry data.
- Analysis of new classification criteria for vasculitic conditions.
Main Results:
- Several agents (rituximab, cyclophosphamide, upadacitinib, baricitinib, mepolizumab, benralizumab, tocilizumab) demonstrated treatment benefits.
- New classification criteria for AAV, giant cell arteritis, and Takayasu arteritis have methodological issues hindering adoption.
Conclusions:
- Emerging data offer potential to transform systemic vasculitis management.
- Addressing current limitations in classification criteria is crucial for patient care and research.
More Related Videos
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Endocarditis III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Myocarditis IV: Nursing Management